ArticleThe American journal of tropical medicine and hygiene2025
Plasmodium falciparum Kelch13 Variants and Histidine-Rich Protein 2/3 Deletions in Central Ethiopia, 2023.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Continental-scale genomic surveillance of Plasmodium falciparum malaria across sub-Saharan Africa with rapid nanopore sequencing.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethiopia faces an increase in Plasmodium falciparum resistant to rapid diagnostic test (RDT) detection based on histidine-rich proteins (HRPs) because of deletions of the encoding genes (pfhrp2/3). Simultaneously, P. falciparum Kelch13 (pfk13) artemisinin partial resistance markers, particularly R622I, are common in northern and western Ethiopia. We assessed pfhrp2/3, pfk13, and Plasmodium falciparum multidrug resistance 1 (pfmdr1) variants among 220 symptomatic malaria patients presenting at health facilities in central Ethiopia in 2023. Plasmodium falciparum infection was present in 86.4%, Plasmodium vivax infection was present in 12.3%, and Plasmodium ovale infection was present in 3.6% of collected isolates. Among P. falciparum infections, the validated artemisinin partial resistance marker pfk13 R622I occurred in 1.1% (n = 2/174), and candidate marker P441L occurred in 1.7% (n = 3/174). pfhrp2, pfhrp3, and dual deletions were seen in 24.0% (n = 36/150), 78.8% (n = 118/150), and 22.7% (n = 34/150), respectively. The pfmdr1 pattern indicated reduced lumefantrine sensitivity. These data suggest that high proportions of P. falciparum infections are being missed by HRP-based RDTs, whereas pfk13 mutations are relatively rare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.